Nabriva Therapeutics plc Long-Term Debt, Maturity, Year Three
Nabriva Therapeutics plc had Long-Term Debt, Maturity, Year Three of $197.00 thousand as of 2023-03-31, per its 10-Q filed 2023-05-22.
Discontinued › Notes › Commitment and Contingencies › Long-Term Debt, Fiscal Year Maturity › Long-Term Debt, Maturity, Year Two and Three
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree · last filed 2023-05-22
- 2023-03-31: Long-Term Debt, Maturity, Year Three $197.00K.
- 2022-12-31: Long-Term Debt, Maturity, Year Three $194.00K.
- 2022-09-30: Long-Term Debt, Maturity, Year Three $178.00K.
- 2022-06-30: Long-Term Debt, Maturity, Year Three $175.00K.
| Period end | Long-Term Debt, Maturity, Year Three |
|---|---|
| 2023-03-31 | $197.00K 10-Q · filed 2023-05-22 |
| 2022-12-31 | $194.00K 10-K · filed 2023-04-17 |
| 2022-09-30 | $178.00K 10-Q · filed 2022-11-10 |
| 2022-06-30 | $175.00K 10-Q · filed 2022-08-03 |
| 2022-03-31 | $208.00K 10-Q · filed 2022-05-05 |
| 2021-09-30 | $4.81M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $4.81M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $4.08M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $4.08M 10-K · filed 2021-03-11 |
| 2020-09-30 | $2.49M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $2.49M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $2.49M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $17.45M 10-K · filed 2020-03-12 |
| 2019-09-30 | $8.88M 10-Q · filed 2019-11-12 |
| 2019-06-30 | $8.68M 10-Q · filed 2019-08-08 |
| 2019-03-31 | $8.59M 10-Q · filed 2019-05-10 |
| 2018-12-31 | $8.59M 10-K · filed 2019-03-12 |